These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

905 related articles for article (PubMed ID: 15121988)

  • 1. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
    Kishnani PS; Goldenberg PC; DeArmey SL; Heller J; Benjamin D; Young S; Bali D; Smith SA; Li JS; Mandel H; Koeberl D; Rosenberg A; Chen YT
    Mol Genet Metab; 2010 Jan; 99(1):26-33. PubMed ID: 19775921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.
    Van den Hout JM; Reuser AJ; de Klerk JB; Arts WF; Smeitink JA; Van der Ploeg AT
    J Inherit Metab Dis; 2001 Apr; 24(2):266-74. PubMed ID: 11405345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy and immunotherapy lead to significant functional improvement in two children with Pompe disease: a case report.
    Castellar-Leones SM; Ortiz-Corredor F; Manrique-Hernández D; Sánchez-Peñarete D; Ruiz-Ospina E; Soto-Peña D; Correa-Arrieta C
    J Med Case Rep; 2024 Jul; 18(1):328. PubMed ID: 39020349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L; Straub V; Neudorf U; Voit T
    Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study.
    van Gelder CM; Poelman E; Plug I; Hoogeveen-Westerveld M; van der Beek NAME; Reuser AJJ; van der Ploeg AT
    J Inherit Metab Dis; 2016 May; 39(3):383-390. PubMed ID: 26768149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.
    Kishnani PS; Nicolino M; Voit T; Rogers RC; Tsai AC; Waterson J; Herman GE; Amalfitano A; Thurberg BL; Richards S; Davison M; Corzo D; Chen YT
    J Pediatr; 2006 Jul; 149(1):89-97. PubMed ID: 16860134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients.
    Poelman E; van den Dorpel JJA; Hoogeveen-Westerveld M; van den Hout JMP; van der Giessen LJ; van der Beek NAME; Pijnappel WWMP; van der Ploeg AT
    J Inherit Metab Dis; 2020 Nov; 43(6):1243-1253. PubMed ID: 32506446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
    Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
    Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRIM-negative infantile Pompe disease: 42-month treatment outcome.
    Rohrbach M; Klein A; Köhli-Wiesner A; Veraguth D; Scheer I; Balmer C; Lauener R; Baumgartner MR
    J Inherit Metab Dis; 2010 Dec; 33(6):751-7. PubMed ID: 20882352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.
    Van den Hout H; Reuser AJ; Vulto AG; Loonen MC; Cromme-Dijkhuis A; Van der Ploeg AT
    Lancet; 2000 Jul; 356(9227):397-8. PubMed ID: 10972374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M; Zhang L; Quan S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
    Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
    Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical immunologic response in a patient with CRIM-negative Pompe disease.
    Abbott MA; Prater SN; Banugaria SG; Richards SM; Young SP; Rosenberg AS; Kishnani PS
    Mol Genet Metab; 2011 Dec; 104(4):583-6. PubMed ID: 21889385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
    Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
    Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of Pompe disease treated with acid alpha-glucosidase].
    Kapica-Topczewska K; Tarasiuk J; Kułakowska A; Drozdowski W
    Neurol Neurochir Pol; 2008; 42(4):353-7. PubMed ID: 18975241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.